Published in Int J Vasc Med on October 03, 2011
Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther (1992) 2.16
Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation (1999) 1.73
Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet (2001) 1.67
Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest (2006) 1.38
Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J Cell Physiol (2002) 1.15
Ageing of the heart. Br J Biomed Sci (1998) 1.12
Role of endogenous bradykinin in human coronary vasomotor control. Circulation (1995) 1.04
Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension (2008) 0.96
Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension (1997) 0.94
Receptors for bradykinin and related kinins: a critical analysis. Can J Physiol Pharmacol (1993) 0.93
Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation (1997) 0.93
Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens (2000) 0.91
Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab (2006) 0.90
Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am J Physiol (1997) 0.89
Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. J Am Coll Cardiol (2002) 0.87
Age-related changes of bradykinin B1 and B2 receptors in rat heart. Am J Physiol Heart Circ Physiol (2005) 0.87
Expression of bradykinin receptors in the left ventricles of rats with pressure overload hypertrophy and heart failure. J Hypertens (2003) 0.85
Promoter polymorphism of the beta2 bradykinin receptor gene is associated with essential hypertension. Jpn Circ J (1999) 0.83
Bradykinin-induced growth inhibition of normal rat kidney (NRK) cells is paralleled by a decrease in epidermal-growth-factor receptor expression. Biochem J (1994) 0.82
Genetic variation in the promoter region of the beta2 bradykinin receptor gene is associated with essential hypertension in a Chinese Han population. Hypertens Res (2001) 0.82
Lack of association of a 9 bp insertion/deletion polymorphism within the bradykinin 2 receptor gene with myocardial infarction. Clin Sci (Lond) (2004) 0.82
Preserved vasodilator effect of bradykinin in dogs with heart failure. Circulation (1999) 0.81
Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts. Am J Physiol (1993) 0.80
Hyperglycaemia abolishes the antihypertrophic efficacy of bradykinin in rat ventricular myocytes. Clin Exp Pharmacol Physiol (1999) 0.78
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One (2010) 3.15
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation (2007) 2.54
Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol (2005) 2.07
A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens (2003) 1.96
Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem (2004) 1.91
IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice. J Clin Invest (2011) 1.77
Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation (2007) 1.73
Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2003) 1.68
Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol (2003) 1.68
Serum tryptase levels in acute coronary syndromes. Int J Cardiol (2005) 1.64
Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol (2011) 1.55
Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J (2013) 1.48
Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol (2008) 1.46
Pranlukast, a cysteinyl leukotriene type 1 receptor antagonist, attenuates the progression but not the onset of silica-induced pulmonary fibrosis in mice. Int Arch Allergy Immunol (2012) 1.46
Acute psychological stress accelerates reverse cholesterol transport via corticosterone-dependent inhibition of intestinal cholesterol absorption. Circ Res (2012) 1.43
Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur Heart J (2007) 1.42
Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med (2006) 1.39
Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J Biol Chem (2013) 1.31
Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol (2003) 1.25
OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J Biol Chem (2007) 1.23
Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun (2003) 1.19
Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem (2003) 1.17
Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol (2004) 1.15
Role of complement activation in atherosclerosis. Curr Opin Lipidol (2003) 1.14
Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol (2007) 1.09
Inflammatory angiogenesis in atherogenesis--a double-edged sword. Ann Med (2008) 1.09
Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol (2004) 1.05
Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis (2007) 1.05
Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol (2007) 1.03
Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol (2006) 1.02
Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity. J Lipid Res (2008) 1.01
MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease. Ann Med (2015) 1.00
Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J (2006) 1.00
Mast cells in vulnerable atherosclerotic plaques--a view to a kill. J Cell Mol Med (2007) 0.96
Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J Lipid Res (2006) 0.96
C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles. Biochem Biophys Res Commun (2005) 0.96
Mast cell chymase induces smooth muscle cell apoptosis by disrupting NF-kappaB-mediated survival signaling. Exp Cell Res (2006) 0.95
Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem (2004) 0.95
Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun (2006) 0.95
A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem (2006) 0.94
An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann Med (2009) 0.94
Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis. Curr Opin Lipidol (2009) 0.94
Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J (2002) 0.94
Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more. Arterioscler Thromb Vasc Biol (2002) 0.94
Function and regulation of the complement system in cardiovascular diseases. Front Biosci (2007) 0.94
Estimation of VLDL, IDL, LDL, HDL2, apoA-I, and apoB from the Friedewald inputs--apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann Med (2009) 0.94
Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol (2002) 0.94
Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am J Cardiol (2004) 0.93
Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells--a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol (2003) 0.93
Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion. Coron Artery Dis (2006) 0.93
Microarray analysis reveals overexpression of CD163 and HO-1 in symptomatic carotid plaques. Arterioscler Thromb Vasc Biol (2006) 0.93
Atomistic simulations of phosphatidylcholines and cholesteryl esters in high-density lipoprotein-sized lipid droplet and trilayer: clues to cholesteryl ester transport and storage. Biophys J (2009) 0.93
Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis (2006) 0.92
Three-dimensional cryoEM reconstruction of native LDL particles to 16Å resolution at physiological body temperature. PLoS One (2011) 0.92
Lipid body formation during maturation of human mast cells. J Lipid Res (2011) 0.91
Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun (2003) 0.91
Enhanced extracellular lipid accumulation in acidic environments. Curr Opin Lipidol (2006) 0.91
Proteolysis of the pericellular matrix: a novel element determining cell survival and death in the pathogenesis of plaque erosion and rupture. Arterioscler Thromb Vasc Biol (2004) 0.91
Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations. PLoS Comput Biol (2012) 0.91
Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev (2014) 0.91
Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis (2008) 0.91
Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2011) 0.91
OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol (2005) 0.90
Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev (2010) 0.90
Expression of antizyme inhibitor 2 in mast cells and role of polyamines as selective regulators of serotonin secretion. PLoS One (2009) 0.90
Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells. World J Gastroenterol (2011) 0.89
Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol (2002) 0.89
Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol (2002) 0.89
OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells. Atherosclerosis (2010) 0.88
Human mast cells arise from a common circulating progenitor. J Allergy Clin Immunol (2013) 0.88
High negative charge-to-size ratio in polyphosphates and heparin regulates factor VII-activating protease. FEBS J (2009) 0.88
ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovasc Disord (2009) 0.88
Gene expression differences between stroke-associated and asymptomatic carotid plaques. J Mol Med (Berl) (2011) 0.88
Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microb Pathog (2007) 0.88
Mast cell-mediated apoptosis of endothelial cells in vitro: a paracrine mechanism involving TNF-alpha-mediated down-regulation of bcl-2 expression. J Cell Physiol (2003) 0.87
Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. J Am Coll Cardiol (2002) 0.87
Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol (2004) 0.87
Activated mast cells increase the level of endothelin-1 mRNA in cocultured endothelial cells and degrade the secreted Peptide. Arterioscler Thromb Vasc Biol (2002) 0.87